Search results
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval...
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company...
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
Zacks via Yahoo Finance· 6 months agoAxsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat...
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Zacks via Yahoo Finance· 4 weeks agoAxsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol...
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
Zacks via Yahoo Finance· 2 years agoThe FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major...
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
Zacks via Yahoo Finance· 1 year agoAxsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The...
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
Zacks via Yahoo Finance· 12 months agoAxsome Therapeutics, Inc. AXSM incurred an adjusted loss 22 cents per share in the first quarter of...
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics AXSM is progressing well with the launch of its first product, Auvelity...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics AXSM announced that the first patient has been enrolled in the ADVANCE-2 phase...